References
- Sternberg C N. Hormone refractory metastatic prostate cancer. Ann Oncol 1992; 3: 331–335
- Slack N H, Murphy G P. A dècade of experience with chemotherapy for prostate cancer. Urology 1983; 22: 1–7
- Eisenberger M A, Simon R, O'Dwyer P J, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827–841
- Jones W G, Fossa S D, Bono A V, et al. Mitomycin-C in the treatment of metastatic prostate cancer: Report on an EORTC phase II study. World J Urol 1986; 4: 182–185
- Delaere K PJ, Leliefeld H, Peulen F, et al. Phase II study of epirubicin in advanced hormone refractory prostate carcinoma. Br J Urol 1992; 70: 641–642
- Jones W G, Fossa S D, Bono A V, et al. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep 1987; 71: 1317
- Burk K. Weekly chemotherapeutic regimen in metastatic prostate cancer. Epirubicin in Urological Oncology: Perspective for a Second Decade, Symp, Nijmegen, June, 1989
- Francini G, Leone V, Pedrioli R, et al. Weekly therapy with epirubicin in advanced prostatic cancer. 5th Europ Conf on Clin Oncol, London, 1989, abstr no 0-0784
- Slack N H, Brady M F, Murphy G P, et al. A reevaluation of the stable category for evaluating response in patients with advanced prostate cancer. Cancer 1984; 54: 564–574
- Perez C A, Fair W R, Ihde D C. Carcinoma of the prostate. Cancer. Principles and Practice of Oncology, V T De-Vita, S Hellman, S A Rosenberg. JB Lippincott, Philadelphis 1989; 1023–1058, chapter 33
- Crawford E D, McLeod D, Dorr A, et al. A comparison of leuprolide with flutamide and leuprolide in previously untreated patients with clinical stage D2 cancer of the prostate. J Urol 1987; 137: 256A
- Pummer K, Stettner H, Lehert M. Phase III study of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Proc Am Soc Clin Oncol 1993; 12: 229